These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23041271)

  • 1. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
    Saha S; Chan DS; Lee CY; Wong W; New LS; Chui WK; Yap CW; Chan EC; Ho HK
    Eur J Pharmacol; 2012 Dec; 697(1-3):13-23. PubMed ID: 23041271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
    Saha S; New LS; Ho HK; Chui WK; Chan EC
    Toxicol Lett; 2010 Feb; 192(2):141-9. PubMed ID: 19854250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.
    Alvarez-Sanchez R; Montavon F; Hartung T; Pähler A
    Chem Res Toxicol; 2006 Aug; 19(8):1106-16. PubMed ID: 16918252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
    Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
    Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
    Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
    Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes.
    Saha S; New LS; Ho HK; Chui WK; Chan EC
    Toxicol Lett; 2010 Jun; 195(2-3):135-41. PubMed ID: 20307632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
    Salamone S; Colin C; Grillier-Vuissoz I; Kuntz S; Mazerbourg S; Flament S; Martin H; Richert L; Chapleur Y; Boisbrun M
    Eur J Med Chem; 2012 May; 51():206-15. PubMed ID: 22409968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.
    Vansant G; Pezzoli P; Saiz R; Birch A; Duffy C; Ferre F; Monforte J
    Int J Toxicol; 2006; 25(2):85-94. PubMed ID: 16597547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells.
    Keil AM; Frederick DM; Jacinto EY; Kennedy EL; Zauhar RJ; West NM; Tchao R; Harvison PJ
    Toxicol In Vitro; 2015 Oct; 29(7):1887-96. PubMed ID: 26193171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
    Guo L; Zhang L; Sun Y; Muskhelishvili L; Blann E; Dial S; Shi L; Schroth G; Dragan YP
    Mol Divers; 2006 Aug; 10(3):349-60. PubMed ID: 17031537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand.
    Nonaka M; Tazuma S; Hyogo H; Kanno K; Chayama K
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e198-206. PubMed ID: 17868335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes.
    Spagnolo A; Grant EN; Glick R; Lichtor T; Feinstein DL
    Neurosci Lett; 2007 Apr; 417(1):72-7. PubMed ID: 17324516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
    Bordessa A; Colin-Cassin C; Grillier-Vuissoz I; Kuntz S; Mazerbourg S; Husson G; Vo M; Flament S; Martin H; Chapleur Y; Boisbrun M
    Eur J Med Chem; 2014 Aug; 83():129-40. PubMed ID: 24953030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
    Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
    Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
    Masubuchi Y
    Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.
    Kassahun K; Pearson PG; Tang W; McIntosh I; Leung K; Elmore C; Dean D; Wang R; Doss G; Baillie TA
    Chem Res Toxicol; 2001 Jan; 14(1):62-70. PubMed ID: 11170509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model.
    Edling Y; Sivertsson LK; Butura A; Ingelman-Sundberg M; Ek M
    Toxicol In Vitro; 2009 Oct; 23(7):1387-95. PubMed ID: 19631733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved.
    He K; Talaat RE; Pool WF; Reily MD; Reed JE; Bridges AJ; Woolf TF
    Drug Metab Dispos; 2004 Jun; 32(6):639-46. PubMed ID: 15155556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
    Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
    Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.